Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: A critical role for Thioredoxin- Interacting protein in diabetes-related impairment of angiogenesis
Author: Dunn, L.
Simpson, P.
Prosser, H.
Lecce, L.
Yuen, G.
Buckle, A.
Sieveking, D.
Vanags, L.
Lim, P.
Chow, R.
Lam, Y.
Clayton, Z.
Bao, S.
Davies, M.
Stadler, N.
Celermajer, D.
Stocker, R.
Bursill, C.
Cooke, J.
Ng, M.
Citation: Diabetes, 2014; 63(2):675-687
Publisher: American Diabetes Association
Issue Date: 2014
ISSN: 0012-1797
Statement of
Louise L. Dunn, Philippa J.L. Simpson, Hamish C. Prosser, Laura Lecce, Gloria S.C. Yuen, Andrew Buckle, Daniel P. Sieveking, Laura Z. Vanags, Patrick R. Lim, Renee W.Y. Chow, Yuen Ting Lam, Zoe Clayton, Shisan Bao, Michael J. Davies, Nadina Stadler, David S. Celermajer, Roland Stocker, Christina A. Bursill, John P. Cooke, and Martin K.C. Ng
Abstract: Impaired angiogenesis in ischemic tissue is a hallmark of diabetes. Thioredoxin-interacting protein (TXNIP) is an exquisitely glucose-sensitive gene that is overexpressed in diabetes. As TXNIP modulates the activity of the key angiogenic cytokine vascular endothelial growth factor (VEGF), we hypothesized that hyperglycemia-induced dysregulation of TXNIP may play a role in the pathogenesis of impaired angiogenesis in diabetes. In the current study, we report that high glucose– mediated overexpression of TXNIP induces a widespread impairment in endothelial cell (EC) function and survival by reducing VEGF production and sensitivity to VEGF action, findings that are rescued by silencing TXNIP with small interfering RNA. High glucose–induced EC dysfunction was recapitulated in normal glucose conditions by overexpressing either TXNIP or a TXNIP C247S mutant unable to bind thioredoxin, suggesting that TXNIP effects are largely independent of thioredoxin activity. In streptozotocin-induced diabetic mice, TXNIP knockdown to nondiabetic levels rescued diabetes-related impairment of angiogenesis, arteriogenesis, blood flow, and functional recovery in an ischemic hindlimb. These findings were associated with in vivo restoration of VEGF production to nondiabetic levels. These data implicate a critical role for TXNIP in diabetes-related impairment of ischemia-mediated angiogenesis and identify TXNIP as a potential therapeutic target for the vascular complications of diabetes.
Keywords: Muscle, Skeletal
Rights: © 2014 by the American Diabetes Association. See http://creativecommons .org/licenses/by-nc-nd/3.0/ for details.
RMID: 0030067889
DOI: 10.2337/db13-0417
Grant ID:
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_105150.pdfPublished Version1.89 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.